{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T10:46:57Z","timestamp":1781347617030,"version":"3.54.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T00:00:00Z","timestamp":1721433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ibroneuroreports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IBRO Neuroscience Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ibneur.2024.07.005","type":"journal-article","created":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T14:46:28Z","timestamp":1721573188000},"page":"207-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy of preladenant in improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"17","author":[{"given":"Mohammad Amin","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Ghajari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Etemadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges Safar","family":"Firouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Mohammadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimia","family":"Janeshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Darvishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafagh","family":"Asgarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayedeh-Fatemeh","family":"Sadat-Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abbasalizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Jafari","family":"Shendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata Akhtari","family":"Kohnehshahri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloofar","family":"Deravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amirhossein","family":"Mazhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Bidares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaddeseh","family":"Belbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdyieh","family":"Naziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein Ashkpour","family":"Motlagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ibneur.2024.07.005_bib1","unstructured":"Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson\u2019s disease - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/36053386\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib2","unstructured":"An update on the management of young-onset Parkinson\u2019s disease - PMC [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6065598\/\u3009."},{"issue":"3","key":"10.1016\/j.ibneur.2024.07.005_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","article-title":"Adenosine A(2A) receptor antagonist treatment of Parkinson\u2019s disease","volume":"61","author":"Bara-Jimenez","year":"2003","journal-title":"Neurology"},{"issue":"10291","key":"10.1016\/j.ibneur.2024.07.005_bib4","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ibneur.2024.07.005_bib5","unstructured":"Challenges in Parkinson\u2019s disease: restoration of the nigrostriatal dopamine system is not enough - ScienceDirect [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1474442204007409\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib6","unstructured":"Dopamine receptors and Parkinson\u2019s disease - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/25954517\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib7","unstructured":"Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/15668416\/\u3009."},{"issue":"6","key":"10.1016\/j.ibneur.2024.07.005_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/mds.25395","article-title":"Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson\u2019s disease","volume":"28","author":"Factor","year":"2013","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.ibneur.2024.07.005_bib9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","article-title":"Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res","volume":"14","author":"Fink","year":"1992","journal-title":"Mol. Brain Res"},{"key":"10.1016\/j.ibneur.2024.07.005_bib10","unstructured":"Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 - PubMed [Internet]. [cited 2024 Jun 7]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28931491\/."},{"key":"10.1016\/j.ibneur.2024.07.005_bib11","unstructured":"Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/30287051\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.08.020","article-title":"Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson\u2019s disease","volume":"32","author":"Hattori","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"3","key":"10.1016\/j.ibneur.2024.07.005_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1474-4422(11)70012-6","article-title":"Preladenant in patients with Parkinson\u2019s disease and motor fluctuations: a phase 2, double-blind, randomised trial","volume":"10","author":"Hauser","year":"2011","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.ibneur.2024.07.005_bib14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/jamaneurol.2015.2268","article-title":"Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned","volume":"72","author":"Hauser","year":"2015","journal-title":"JAMA Neurol."},{"issue":"11 Suppl 6","key":"10.1016\/j.ibneur.2024.07.005_bib15","first-page":"S32","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ibneur.2024.07.005_bib16","unstructured":"Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson\u2019s disease patients - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/19050033\/\u3009."},{"issue":"11 Suppl 6","key":"10.1016\/j.ibneur.2024.07.005_bib17","first-page":"S44","article-title":"Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists","volume":"61","author":"Mori","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ibneur.2024.07.005_bib18","unstructured":"Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology - PubMed [Internet]. [cited 2024a Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/31733690\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib19","unstructured":"(15) Parkinson\u2019s disease: A review | Request PDF [Internet]. [cited 2024b Jun 7]. Available from: \u3008https:\/\/www.researchgate.net\/publication\/259587074_Parkinson%27s_disease_A_review\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib20","unstructured":"Parkinson\u2019s disease: Autoimmunity and neuroinflammation - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/27497913\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib21","unstructured":"Patient and caregiver characteristics associated with caregiver burden in Parkinson\u2019s disease: a palliative care approach - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/31735048\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib22","unstructured":"Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease - PubMed [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/pubmed.ncbi.nlm.nih.gov\/20216409\/\u3009."},{"issue":"8","key":"10.1016\/j.ibneur.2024.07.005_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/syn.20410","article-title":"Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease","volume":"61","author":"Pinna","year":"2007","journal-title":"Synapse"},{"issue":"6","key":"10.1016\/j.ibneur.2024.07.005_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10928-022-09825-9","article-title":"A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson\u2019s disease: application to preladenant","volume":"49","author":"Rose","year":"2022","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ibneur.2024.07.005_bib25","unstructured":"Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis | BMC Psychiatry | Full Text [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-018-1910-9\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib26","unstructured":"Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors - PMC [Internet]. [cited 2024 Jun 7]. Available from: \u3008https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8270692\/\u3009."},{"key":"10.1016\/j.ibneur.2024.07.005_bib27","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/fnl.13.52","article-title":"Preladenant: An adenosine A2A receptor antagonist for Parkinson\"s disease","volume":"8","author":"Zu\u00f1iga-Ram\u00edrez","year":"2013","journal-title":"Future Neurol."}],"container-title":["IBRO Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242124000666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667242124000666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T08:44:40Z","timestamp":1734597880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667242124000666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"alternative-id":["S2667242124000666"],"URL":"https:\/\/doi.org\/10.1016\/j.ibneur.2024.07.005","relation":{},"ISSN":["2667-2421"],"issn-type":[{"value":"2667-2421","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of preladenant in improving motor symptoms in Parkinson's disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"IBRO Neuroscience Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ibneur.2024.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of International Brain Research Organization.","name":"copyright","label":"Copyright"}]}}